Advances in radiotherapy technology and technique over the last 3 decades have revolutionized radiation treatment options for genitourinary malignancies. The development of more focused and accurate radiation treatment has facilitated safe delivery of dose-escalated treatment that improves disease control and the development of shorter-duration hypofractionated treatment regimens that are more convenient for patients and improve access to treatment. The management of oligometastatic disease is evolving with ablative treatment of oligometastasis and the primary for select patients and shorter-duration palliative treatment regimens. Work is ongoing to personalize radiation treatment regimens for genitourinary malignancies based on molecular biomarkers.

过去 3 年放射治疗技术和技术的进步彻底改变了泌尿生殖系统恶性肿瘤的放射治疗选择。更集中和更准确的放射治疗的发展促进了剂量递增治疗的安全实施，从而改善了疾病控制，并促进了对患者更方便并改善治疗可及性的更短持续时间的大分割治疗方案的开发。寡转移性疾病的管理正在随着寡转移灶的消融治疗和选定患者的主要治疗以及持续时间较短的姑息治疗方案而不断发展。基于分子生物标志物的泌尿生殖系统恶性肿瘤放射治疗方案的个性化工作正在进行中。